Table 3 Multivariable Cox proportional hazards model, propensity score-adjustment, and IPTW analyses of the effect of co-administration of PPIs on overall survival of the entire population (capecitabine monotherapy and CapeOX regimen).

From: Proton pump inhibitors affect capecitabine efficacy in patients with stage II–III colorectal cancer: a multicenter retrospective study

     

Multivariable analysis

Adjusted for propensity score

IPTW

Variables

No.

Event

Censored

HR (95% CI)

P-value

Posterior probability

HR (95% CI)

P-value

Posterior probability

HR (95% CI)

P-value

Posterior probability

PPI

Yes

54

8

46

1.26 (0.58–2.71)

0.560

0.308

1.12 (0.53–2.40)

0.767

0.422

1.21 (0.54–2.73)

0.642

0.347

 

No

552

66

486

1

  

1

  

1

  

Age (10-year intervals)

–

–

–

0.95 (0.76–1.20)

0.683

       

Sex

Male

328

48

280

1.57 (0.97–2.56)

0.066

       

Female

278

26

252

1

        

Primary site

Right-sided colon

171

26

145

1.27 (0.78–2.08)

0.336

       

Others

435

48

387

1

        

Stage

III high-risk

199

47

152

2.78 (1.23–6.29)

0.014

       

III low-risk

334

20

314

0.63 (0.27–1.50)

0.300

       

II

73

7

66

1

        

Regimen

CapeOX

157

24

133

0.95 (0.55–1.64)

0.855

       

Capecitabine

449

50

399

1

        

RDI (10% intervals)

–

–

–

0.88 (0.80–0.97)

0.011

       
  1. Abbreviations: CapeOX, capecitabine and oxaliplatin; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; PPI, proton pump inhibitor; RDI, relative dose intensity.
Back to article page